Viridian Therapeutics Inc (NAS:VRDN)

$ 12.34 0.74 (6.38%) Market Cap: 787.57 Mil Enterprise Value: 347.92 Mil PE Ratio: 0 PB Ratio: 2.06 GF Score: 46/100

Q1 2024 Viridian Therapeutics Inc Earnings Call Transcript
May 08, 2024

$14.9 (-1.59%)

Earnings
Viridian Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Viridian Therapeutics Inc Subcutaneous IGF-1R Program Selection Transcript
Dec 18, 2023
Viridian Therapeutics Inc VRDN-001 Chronic TED Data Conference Call Transcript
Jul 10, 2023
Q1 2023 Viridian Therapeutics Inc Earnings Call Transcript
May 09, 2023

$25.68 (+0.75%)

Earnings
Q4 2022 Viridian Therapeutics Inc Earnings Call Transcript
Mar 08, 2023

$29.47 (-10.48%)

Earnings
Viridian Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Q3 2022 Viridian Therapeutics Inc Earnings Call Transcript
Nov 14, 2022

$20.32 (-0.93%)

Earnings
Q2 2022 Viridian Therapeutics Inc Earnings Call Transcript
Aug 15, 2022

$22 (+49.36%)

Earnings
Q1 2022 Viridian Therapeutics Inc Earnings Call Transcript
May 12, 2022

$10.56 (+5.49%)

Earnings
Q4 2021 Viridian Therapeutics Inc Earnings Call Transcript
Mar 10, 2022

$19.04 (-3.05%)

Earnings
Viridian Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Viridian Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 03, 2021
Q4 2020 Viridian Therapeutics Inc Earnings Call Transcript
Mar 25, 2021

$17.27 (-1.26%)

Earnings
Viridian Therapeutics Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
miRagen Therapeutics Inc Extraordinary Shareholders Meeting Transcript
Dec 31, 2020
Miragen Therapeutics, Inc., Viridian Therapeutics, Inc. - M&A Call Transcript
Oct 28, 2020
Q2 2020 miRagen Therapeutics Inc Earnings Call Transcript
Aug 05, 2020

$17.55 (+2.63%)

Earnings
Miragen Therapeutics - Special Call Transcript
Jun 23, 2020
miRagen Therapeutics Inc Annual Shareholders Meeting Transcript
May 21, 2020
Q1 2020 miRagen Therapeutics Inc Earnings Call Transcript
May 07, 2020

$8.25 (-3.51%)

Earnings
Q4 2019 miRagen Therapeutics Inc Earnings Call Transcript
Mar 11, 2020

$9.18 (-8.44%)

Earnings
Miragen Therapeutics, Inc. - Special Call Transcript
Dec 11, 2019
Q3 2019 miRagen Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$10.68 (-3.78%)

Earnings
Q2 2019 miRagen Therapeutics Inc Earnings Call Transcript
Aug 07, 2019

$23.55 (+18.05%)

Earnings
miRagen Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 19, 2019
Q1 2019 miRagen Therapeutics Inc Earnings Call Transcript
May 08, 2019

$42.15 (-0.35%)

Earnings
Q4 2018 miRagen Therapeutics Inc Earnings Call Transcript
Mar 13, 2019

$39.75 (+3.52%)

Earnings

Viridian Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 10:15PM GMT

Release Date Price: $32.98 (+20.10%)

Transcript

Unidentified Analyst

Is this live? Sure enough. There we go. Great. Good afternoon. Thanks, everyone, for joining us. So to everyone here for the presentation today, we're thrilled to have the Viridian team with us. We've got Jon Violin and we really appreciate having everyone here at the conference. I'll go ahead and pass it over to him to make the most of the time. But thanks so much, and welcome again.

Jonathan Violin

Viridian Therapeutics, Inc. - Co-Founder, CEO, President & Director

Thank you, James, and pleasure to be here to share an overview of Viridian. Before I begin, of course, I'll be making some forward-looking statements. Please see our SEC filings for important disclosures. So Viridian is developing best-in-class medicines for patients suffering from serious and rare diseases. We were founded in 2020. We're based in Waltham, Massachusetts, just outside Boston, with about 90 employees. And our market cap after some exciting news yesterday morning that I'll discuss more details now approaching $2 billion with an initial focus on thyroid eye disease

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.